Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.

Reni M, Orsi G, Carconi C, Malleo G, Procaccio L, Macchini M, Bencardino K, Merelli B, Pretta A, Rapposelli IG, Pecorelli N, Partelli S, Sperti E, Crippa S, Liscia N, Di Marco M, Milella M, Lonardi S, Palumbo D, Torri V, Falconi M

Open source

DOI: 10.1016/j.eclinm.2026.104190
Published: 2026 Sep
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.104190,
  title = {Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.},
  author = {Reni M and Orsi G and Carconi C and Malleo G and Procaccio L and Macchini M and Bencardino K and Merelli B and Pretta A and Rapposelli IG and Pecorelli N and Partelli S and Sperti E and Crippa S and Liscia N and Di Marco M and Milella M and Lonardi S and Palumbo D and Torri V and Falconi M},
  year = {2026},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.104190},
  url = {https://doi.org/10.1016/j.eclinm.2026.104190}
}

RIS

TY  - JOUR
TI  - Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.
AU  - Reni M
AU  - Orsi G
AU  - Carconi C
AU  - Malleo G
AU  - Procaccio L
AU  - Macchini M
AU  - Bencardino K
AU  - Merelli B
AU  - Pretta A
AU  - Rapposelli IG
AU  - Pecorelli N
AU  - Partelli S
AU  - Sperti E
AU  - Crippa S
AU  - Liscia N
AU  - Di Marco M
AU  - Milella M
AU  - Lonardi S
AU  - Palumbo D
AU  - Torri V
AU  - Falconi M
PY  - 2026
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104190
UR  - https://doi.org/10.1016/j.eclinm.2026.104190
ER  -

APA

M, R., G, O., C, C., G, M., L, P., M, M., K, B., B, M., A, P., IG, R., N, P., S, P., E, S., S, C., N, L., M, D. M., M, M., S, L., D, P., V, T., & M, F. (2026). Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104190

Source records

pubmed · retrieved 2026-09-25T20:31:06.982Z